FDA Weighs an mRNA Flu Shot Built on Technology RFK Jr. Has Questioned

The agency is close to a decision on Moderna's mRNA-based influenza vaccine, which would be the first of its kind on the market. The outcome will be read across the biotech sector as a signal about the technology's standing under the current health department.